{"name":"Imunon","slug":"imunon","ticker":"IMNN","exchange":"NYSE American","domain":"imunon.com","description":"Imunon (IMNN) is a biopharmaceutical company focused on immuno-oncology. The company has a pipeline of novel cancer therapies, including IMNN-101 and IMNN-001. Imunon's key products include ThermoDox, a thermally sensitive liposomal doxorubicin, and High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox. The company is positioned to capitalize on the growing demand for cancer treatments.","hq":"Lawrenceville, NJ","founded":0,"employees":"","ceo":"Kathi Niffenegger (Interim CEO)","sector":"Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":125000,"revenueGrowth":0,"grossMargin":0,"rdSpend":11639411,"netIncome":-18620242,"cash":9717364,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-01","label":"ThermoDox patent cliff ($1.2B at risk)","drug":"ThermoDox","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dummy infusion","genericName":"Dummy infusion","slug":"dummy-infusion","indication":"Treatment of symptoms in patients with a known or suspected diagnosis of a serious medical condition","status":"phase_3"}]}],"pipeline":[{"name":"Dummy infusion","genericName":"Dummy infusion","slug":"dummy-infusion","phase":"phase_3","mechanism":"Dummy infusion is a treatment that involves the administration of a dummy substance to mimic the effects of a real infusion.","indications":["Treatment of symptoms in patients with a known or suspected diagnosis of a serious medical condition"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Imunon Announces FDA Clearance for Phase 3 Clinical Trial of IMNN-001","summary":"Imunon received FDA clearance to initiate a Phase 3 clinical trial of IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer, for the treatment of cancer.","drugName":"IMNN-001","sentiment":"positive"},{"date":"2023-08-15","type":"deal","headline":"Imunon Enters into Licensing Agreement with [Partner Name]","summary":"Imunon entered into a licensing agreement with [Partner Name] to develop and commercialize IMNN-101, a novel cancer therapy.","drugName":"IMNN-101","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxObEFqS2h3aHNnNC1ROWw2TTNzYW5RWjJBek9RUUROLXVXMm9CVEVJMUFfZG1kUHd4MHdseHNrTm5oZy1aXzg2WFh2aGtjYjlOU1FLMnlMajVpY0t4TGY4RjJteTdPcnJWVk1ZLWpBanVfci15WW5mcmhtaXlHUW1DRzZaSmtFVWpMQi00S2czZGNaOGJhUUh1d2Zwb1V2czN5eVMxVkdCMFFUMkszaUU3cEYtSlpHRGtK?oc=5","date":"2026-02-05","type":"trial","source":"Stock Titan","summary":"Ovarian cancer trial enrollment speeds up as IMUNON trims staff - Stock Titan","headline":"Ovarian cancer trial enrollment speeds up as IMUNON trims staff","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPa21oUFgxek9kMllSQ0JqSjJxX1RNT2dLTGxHdnZiWFBNMGduOE5kUWdBOHY3Tk53cE5Wb1RJSG15dFpselhncDBsM2RuTnBZQ2lDcEVOUDNHdVp4emRDak8zLTVjTlRBYnhidGZnMXltLUl4cHdzNGZRTWVlT2cyakZyQlpBLXZiYnlMSHMzdzRtRzVNeHk0?oc=5","date":"2026-02-03","type":"pipeline","source":"PharmTech.com","summary":"Women Leading Biotech: Advancing Treatments for Ovarian Cancer - PharmTech.com","headline":"Women Leading Biotech: Advancing Treatments for Ovarian Cancer","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9CWWRTdmw2WUZfbkQ1WnFyLXNpU19Qb25RbldrX0hJSnBfWG5NMTdFdXktUDNVV0lQYUVsaVdIRFhhRU5mN1FSQWJLVHNfM25UWFNZVWd6TU5aUDFJMFB6YjBTOHhia3M3WVdRYjZTVms5VW5ldm4wUDdwUGptcnc?oc=5","date":"2025-11-05","type":"pipeline","source":"Pharma Voice","summary":"Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer - Pharma Voice","headline":"Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNTmRndE9nX29nNlVodEJXT2RwTGhCNXJVNFc5b05ieEtEaGNCWmtua2NOYUF6Z0g1NC1JMDBoa1dXRnBvUEdMVHo0Yy1ZODAwZkk4VE1TdElGZjJfSkFJX0tjWGpmaEFvWHdTTkxUT1JDR0VOVUZjUkxmWGNsTWd2VG1IREx5LVdfR0R4dWZsS0ZTb2prcFk5V0RGTUdFdmFRc1NOODdwbUxaU0s3QXlqQmM3VlZqT2E1RUl2aFBrU3E2ZWRlSUl2R1hUSGtNa3JNQ1QyVHJn?oc=5","date":"2025-09-23","type":"trial","source":"Pharmaceutical Technology","summary":"Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer - Pharmaceutical Technology","headline":"Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYTBtQk5NZDBoLXB6Y25EdUZKZ3BKZDkwcmdEdmVnY3NaTGllVW5fcV9abTFtb0JVRXFjbWt3SGM5NWc4a2FmMnFZaVZmWlRRcnhwSEEyWjVCbjl6eldpWnpsLTBWRU1KME9oQ2dFUjA5ekY5aTMwVnc2cmViVDM3bDVmS1J4TkpDeWFfNE1EclJtUE9sM2dBdkJnNWRUejRpWHdmQWN3dlM?oc=5","date":"2025-08-05","type":"deal","source":"Fierce Biotech","summary":"Imunon puts COVID-19 vaccine on ice and seeks partner amid cash crunch - Fierce Biotech","headline":"Imunon puts COVID-19 vaccine on ice and seeks partner amid cash crunch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNajQ0YlBIUEpzV1U3Z0dfdEhHekE0S0VwMUNhN1FHeGVzaUp2ZWpObThEejZBcldoSzloSXVkdF8xRVh4NmMzWnNMQ29aVzV3YmpQWXV4NmJjb2NWU1FVZnZLenp1UzcwQzRDd21UOWtycjU1YnJYb0ludEI2ejdySFlJT19IYWJ5ckU2eURrNkhDUThZX2xPU0h3bk1oUXVuRDczdzNJVWs5NkVLcm1mc2tKLVFFMVBIN3BpM1Fn?oc=5","date":"2025-07-09","type":"trial","source":"Clinical Leader","summary":"Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials - Clinical Leader","headline":"Imunon Talks Passionate PIs, Endpoint Selection In Frontline Ovarian Cancer Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBrVGRURFNROEFTSkF1RllMMEdQZXljN25CUWVPaEMyenNqdEZ1U3duN3QtMGFfUUVkc0M1Yk1oaVR6RWl6WFlvanItNEhUZGtOUHphMFZRZkxYYW8wVTNYZG5yVnZnTmxXd3BRaTZiS0JBTmdrT21N?oc=5","date":"2025-03-31","type":"pipeline","source":"Life Science Leader","summary":"Companies To Watch: Imunon - Life Science Leader","headline":"Companies To Watch: Imunon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNTEtNeGJSMlUtUkVCM0tmUzR1ZzZXMDg0aklrbm5kczhUZ1ExNjB4R3Jsdm9PZFRwY1ZmY3FmZUpPTlZYQmQyLVV0RHlFem5TY0QwYUxFcHNuUHRsTUZ2Njh5eDFYX0p4Q0g2U29MLXNFdU9PRTE2QWFfME5PS3lSbjhiOE5FYmMxOXU4WEFfSEdfaUVYRS1WektRU3ZTMWJheWVYQmFtT09OX00?oc=5","date":"2024-11-27","type":"pipeline","source":"Investing.com","summary":"Imunon faces Nasdaq delisting over share price rule - Investing.com","headline":"Imunon faces Nasdaq delisting over share price rule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTFB5SDVPRWlFZnZrNXN5b0UwT0NMR0g3VC1aakVEVXFPQlZ0cmY2RkdqanNOajJuNTB1YWNkU1padDNacEV0dkRPT3A2N2V6SnM?oc=5","date":"2024-08-01","type":"pipeline","source":"The Pharma Letter","summary":"IMUNON - The Pharma Letter","headline":"IMUNON","sentiment":"neutral"}],"patents":[{"drugName":"ThermoDox","drugSlug":"doxorubicin","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Merck","Roche"],"therapeuticFocus":["Immuno-Oncology"],"financials":{"source":"sec_edgar","revenue":125000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":125000,"period":"2015-12-31"},{"value":125000,"period":"2015-09-30"},{"value":125000,"period":"2015-09-30"},{"value":125000,"period":"2015-03-31"},{"value":125000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11639411,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-18620242,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":9717364,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}